Transplantation of X-linked severe combined immunodeficient dogs with CD34+ bone marrow cells
Brian J. Hartnett(University of Pennsylvania), Peter J. Felsburg(University of Pennsylvania), Kenneth I. Weinberg(University of Pennsylvania), Richard A. Nash(Colorado Blood Cancer Institute), N. Matthew Ellinwood(Iowa State University), DaPeng Yao(University of Pennsylvania), Peter A. McSweeney(Mesoblast (United States)), Paula S. Henthorn(University of Pennsylvania), Peter F. Moore(University of California, Davis), Jeffrey D. Brown(University of Pennsylvania), Steven E. Suter(North Carolina State University)
Cited by 26
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k